oalib
Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine
Mengjia Qian, Duojiao Wu, Ena Wang, Francesco M Marincola, Wei Wang, William Rhodes, Michael Liebman, Chunxue Bai, Ching-Wan Lam, Gyorgy Marko-Varga, Thomas E Fehniger, Roland Andersson, Xiangdong Wang
Clinical and Translational Medicine , 2012, DOI: 10.1186/2001-1326-1-25
Abstract: This Session focused discussing on new models for project development and promotion in translational medicine. The conference stimulated the scientific and commercial communication of project development between academies and companies, shared the advanced knowledge and expertise of clinical applications, and created the environment for collaborations.Although strategic collaborations between corporate and academic institutions have resulted in a state of resurgence in the market, new cooperation models still need time to tell whether they will improve the translational medicine process.Clinical translational medicine (CTM) is an emerging area comprising multidisciplinary research from basic science to medical applications and entails a close collaboration among hospital, academia and industry [1]. CTM is to bridge the divide between health informatics ‘bench research’ and the application of informatics in clinical and health care settings [2]. The critical care community is beginning to adopt an increasingly translational approach to research, drug development and early-phase clinical trials [3].The 2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM) served as one of the milestone conferences on CTM and was organized by Chinese Academy of Engineering, Chinese Academy of Medical Sciences, The U.S. National Institutes of Health Clinical Center, and Global MD Organization. As a part of 2012 SAS-CTM, session seven, Project Development and Promotion in Translational Medicine, was co-chaired by Dr. Roland Anderson, Professor of Department of Surgery, Clinical Sciences,Medical Faculty, Lund University and Dr. Xiangdong Wang, Professor of Medicine and Director, Biomedical Research Center, Fudan University Zhongshan Hospital. The Session focused on new models for project development and promotion in translational medicine.Translational medicine is a growing and emerging area that integrates basic, social, clinical and political science together to
Clinical and translational medicine: Integrative and practical science.
Edward Abraham, Francesco M Marincola, Zhinan Chen, Xiangdong Wang
Clinical and Translational Medicine , 2012, DOI: 10.1186/2001-1326-1-1
Abstract: Clinical and translational science has been defined as a novel attempt to "translate remarkable scientific innovations into health gains", and is a critical and core component of full-spectrum biomedical research [1]. Translational research as a key word was emphasized and headlined in the National Institutes of Health guide for Specialized Program of Research Excellence (SPORE) grants for cancer research [2]. Furthermore, translational science has been defined as a two-way process to translate discoveries from the bench into clinical application and/or the translation of clinical findings into the understanding of molecular mechanisms [3,4]. Given the growing impact of scientific knowledge and discoveries on clinical practice, translational medicine was initially described as "the marriage between new discoveries in basic science and clinical practice" [5]. Clinical and translational medicine can be used to understand the mechanisms of clinical variation between diseases, pathogenesis, biomarkers, and therapies. For example, translational medicine is involved in determining optimal regimens to alleviate symptoms and improve quality of life. The efficacy and safety of drugs selected from pre-clinical animal models can be translated into applicable and therapeutic approaches for clinical trials [6].Clinical and translational medicine plays a unique and critical role in fostering the flow of bidirectional information between basic and clinical scientists, optimizing new biotechnologies, improving clinical application of new therapeutic concepts, and ultimately improving the quality of life for patients. Clinical and translational medicine integrates clinical research with modern methodologies in systems and computational biology, genomics, proteomics, metabolomics, pharmacomics, transcriptomics, and high-throughput image analysis. It should also foster the implementation of human tissue banking, and the development of bio-banks linked to high quality clinical data bas
A new vision of definition, commentary, and understanding in clinical and translational medicine
Xiangdong Wang
Clinical and Translational Medicine , 2012, DOI: 10.1186/2001-1326-1-5
Abstract: There is growing evidence to the importance of translational science and medicine in the improvement of patient outcome, even though the definitions of translational science, translational medicine, and clinical and translational medicine need to be further clarified. Clinical and translational medicine is expected to include scientific and regulatory investigations to translate preclinical researches to clinical application with a specific emphasis on new biotechnologies, biomaterials, bioengineering, disease-specific biomarkers, cellular and molecular medicine, omics science, bioinformatics, applied immunology, molecular imaging, drug discovery and development, and regulation and health policy. It is believed that clinical and translational medicine will benefit and improve novel diagnostics/prognostics and therapeutics for clinical use, post-genomic knowledge and experience, and/or new disciplines that reflect additional levels of complexity. We should clarify the bioethics at the interface and paradigms between technology and society, academies and industries, as well as publics and private models. Translational medicine should meet the demands of maintaining or expanding the biomedical workforce and education programs that attract and retain young people in the translational and biomedical sciences. In the present perspective, we collected commentaries and descriptions about clinical and translational medicine from some members of Clinical and Translational Medicine editorial board to stimulate the discussion and help the understanding better.Barry S. Coller (David Rockefeller Professor of Medicine; Head, Allen and Frances Adler Laboratory of Blood and Vascular Biology; Physician-in Chief of the Rockefeller University Hospital; and Vice President for Medical Affairs, Rockefeller University) defines translational science as, “The application of the scientific method to address a health need.” In contrast to basic investigation, which has the generation of new kn
Translational Medicine is developing in China: A new venue for collaboration
Xiangdong Wang, Ena Wang, Francesco M Marincola
Journal of Translational Medicine , 2011, DOI: 10.1186/1479-5876-9-3
Abstract: Translational Medicine is an emerging area comprising multidisciplinary Research from basic sciences to medical applications well summarized by the Bench-to-Beside concept; this entails close collaboration between clinicians and basic scientists across institutes. We further clarified that Translational Medicine should be regarded as a two-way road: Bench-to-Bedside and Bedside-to-Bench [1], to complement testing of novel therapeutic strategies in humans with feedback understanding of how human react to the treatment. It is, therefore, critical and important to define and promote Translational Medicine among clinicians, basic Researchers, biotechnologists, politicians, ethicists, sociologists, investors and coordinate these efforts among different Countries [2] fostering aspects germane only to this type of Research such as, as recently discussed, biotechnology entrepreneurship [3]. Moreover, the recognized need to base biomedical discoveries on knowledge derived from human samples should be covered by the development of high quality Biobanks [4] and tools for data mining of existing information [5]. Translational Medicine as an inter-disciplinary science is developing rapidly and widely and, in this article, we will place a special emphasis on China.A first National step toward the promotion of Translational Medicine in China was to hold the first Symposium on Translational Medicine in 2007. Another milestone emphasizing the commitment of this Country to the rapid development of Translational Medicine was the Sino-America Symposium on Clinical and Translational Research co-organized by the GlobalMD Organization, Chinese Academy of Medical Sciences and the U.S. National Institutes of Health Clinical Center in June of 2010 [6]. The meeting aimed at gathering clinicians, Researchers, ethicists and health care officials from hospitals, academia and governmental agencies, involved in human subject Research, multi-national clinical trials, and Translational "bench-to-bed
Clinical proteomics and OMICS clues useful in translational medicine research
Elena Lopez, Luis Madero, Juan Lopez-Pascual, Martin Latterich
Proteome Science , 2012, DOI: 10.1186/1477-5956-10-35
Abstract: Proteomic signatures, specific for multiple diseases, including cancer and pre-invasive lesions, are emerging. This article combines, in a simple manner, relevant proteomic and OMICS clues used in the discovery and development of diagnostic and prognostic biomarkers that are applicable to all clinical fields, thus helping to improve applications of clinical proteomic strategies for translational medicine research.
Translational genomics in personalized medicine – scientific challenges en route to clinical practice
Michael Rossbach, Marta Garcia Martinez de Lecea
The HUGO Journal , 2012, DOI: 10.1186/1877-6566-6-2
Abstract: Personalized medicine generally promises to result in both higher quality in treatment for individual patients and in lower costs in health care since patients will be offered only such therapies that are more effective for them and treatments that will not be safe or effective will be avoided. Recent advancements in biomedical and genomic sciences have paved the way to translate such research into clinical practice and health policies. However, the move towards greater personalization of medicine also comes along with challenges in the development of novel diagnostic and therapeutic tools in a complex framework that assumes that the use of genomic information is part of a translational continuum, which spans from basic to clinical research, preclinical and clinical trials, to policy research and the analysis of health and economic outcomes. The use of next-generation genomic technologies to improve the quality of life and efficiency of healthcare delivered to patients has become a mainstay theme in the field as benefits derived from such approaches include reducing a patient’s need to go through ineffective therapies, lowering side- and off-target effects of drugs, prescribing prophylactic therapies before acute exacerbations, and reducing expenditures.As such, personalized medicine promises to increase the quality of clinical care and, in some cases, to decrease health care costs. Besides the scientific challenges, there are several economic hurdles. For instance, healthcare providers need to know, whether the approach of personalized healthcare is affordable and worth the expenses. In addition, the economic rationale of personalized healthcare includes not only the reduction of the high expense of hospitalizations, the predictive diagnostics that will help to reduce cost through prevention or the increased efficacy of personalized therapies needs to offset prices of drugs. There are also several factors that influence payer adoption, coverage and reimbursement; t
Science Translational Medicine – improving human health care worldwide by providing an interdisciplinary forum for idea exchange between basic scientists and clinical research practitioners
Forsythe, Katherine
GMS Medizin-Bibliothek-Information , 2010,
Abstract: Science Translational Medicine’s mission is to improve human health care worldwide by providing a forum for communication and interdisciplinary idea exchange between basic scientists and clinical research practitioners from all relevant established and emerging disciplines. The weekly journal debuted in October 2009 and is published by the American Association for the Advancement of Science (AAAS), the publisher of Science and Science Signaling. The journal features peer-reviewed research articles, perspectives and commentary, and is guided by an international Advisory Board, led by Chief Scientific Adviser, Elias A. Zerhouni, M.D., former Director of the National Institutes of Health, and Senior Scientific Adviser, Elazer R. Edelman, M.D., Ph.D., Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology, Massachusetts Institute of Technology. The Science Translational Medicine editorial team is led by Katrina L. Kelner, Ph.D., AAAS. A profound transition is required for the science of translational medicine. Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the rapid transformation of this knowledge into effective health measures is not keeping pace with the challenges of global health care. Creative experimental approaches, novel technologies, and new ways of conducting scientific explorations at the interface of established and emerging disciplines are now required to an unprecedented degree if real progress is to be made. To aid in this reinvention, Science and AAAS have created a new interdisciplinary journal, Science Translational Medicine. The following interview exemplefies the pioneering content found in Science Translational Medicine. It is an excerpt from a Podcast interview with Dr. Samuel Broder, former director of the National Cancer Institute and current Chief Medical Officer at Celera. The Podcast was produced in tangent with Dr. Broder’s Research Perspective “Twenty-Five Years of Translational Medicine in Antiretroviral Therapy: Promises to Keep”, published in Science Translational Medicine, 7 July 2010; Volume 2, Issue 39. Dr. Broder’s perspective marks the 25th anniversary of modern antiretroviral drug discovery and development. In the early 1980s, Dr. Broder’s research team adapted the nucleotide analog AZT for treating HIV infection, thus ushering in the era of antiretroviral therapies that have enabled HIV-positive individuals to live longer. The Podcast interview was conducted by Annalisa VanHook, Associate Online Editor, AAAS.
Biomedical informatics and translational medicine
Indra Sarkar
Journal of Translational Medicine , 2010, DOI: 10.1186/1479-5876-8-22
Abstract: Biomedical informatics, by definition[1-8], incorporates a core set of methodologies that are applicable for managing data, information, and knowledge across the translational medicine continuum, from bench biology to clinical care and research to public health. To this end, biomedical informatics encompasses a wide range of domain specific methodologies. In the present discourse, the specific aspects of biomedical informatics that are of direct relevance to translational medicine are: (1) bioinformatics; (2) imaging informatics; (3) clinical informatics; and, (4) public health informatics. These support the transfer and integration of knowledge across the major realms of translational medicine, from molecules to populations. A partnership between biomedical informatics and translational medicine promises the betterment of patient care[9,10] through development of new and better understood interventions used effectively in clinics as well as development of more informed policies and clinical guidelines.The ultimate goal of translational medicine is the development of new treatments and insights towards the improvement of health across populations[11]. The first step in this process is the identification of what interventions might be worthy to consider[12]. Next, directed evaluations (e.g., randomized controlled trials) are used to identify the efficacy of the intervention and to provide further insights into why a proposed intervention works[12]. Finally, the ultimate success of an intervention is the identification of how it can be appropriately scaled and applied to an entire population[12]. The various contexts presented across the translational medicine spectrum enable a "grounding" of biomedical informatics approaches by providing specific scenarios where knowledge management and integration approaches are needed. Between each of these steps, translational barriers are comprised of the challenges associated with the translation of innovations developed through
Tumor biobanks in translational medicine  [cached]
Botti Gerardo,Franco Renato,Cantile Monica,Ciliberto Gennaro
Journal of Translational Medicine , 2012, DOI: 10.1186/1479-5876-10-204
Abstract: The concept of tissue banking as a “bio-repository” aimed to collection, storing and distribution of human biological material and clinical information, is emerging as a successful strategy to support clinical and translational research. In particular, Tumor Biobanks represent a key resource for diagnosis, research and experimental therapies, especially for those correlated to clinical application of a new type of medicine known as “intelligent drugs”. Biobanks are not “spontaneous” collections, but they needs an institutional organization, basically a research unit, whose effectiveness and quality can be guaranteed only if it is carefully organized according to precise and shared rules.
Implementations of translational medicine
Kai-Christian Sonntag
Journal of Translational Medicine , 2005, DOI: 10.1186/1479-5876-3-33
Abstract: The rapid evolutions in science have generated a tremendous spectrum of new technologies and tools in both basic and clinical research/medicine. This includes the constant improvement of old and the discovery of new diagnostics and therapies, which increasingly contain and integrate elements from different fields, such as biomedical and other sciences, modern and traditional medicine and various technology branches. In addition, the application of these developments in clinical settings have created a "feed-back-loop" providing crucial information about their feasibility and success in improving human health. This network of scientific and clinical research/medicine has become one of the factors in shaping modern societies not only by being a major economical factor (see [1] for details), but also by challenging basic values and traditional thinking. To face the emerging challenges of creating a balanced and effective healthcare system, new concepts are needed for providing a framework of integrative strategies and solutions that efficiently combine basic and clinical research/medicine.So far, translational research/medicine has rather been a linear concept rooted in traditional (academic) approaches to provide therapies for diseases (from bench to bedside), while paying little attention to patient-oriented research that involves understanding the underlying cause of disease and its treatments (from bedside to bench). Moreover, not much attention has been paid to many socio-economical aspects that are associated with research or medicine. Therefore, new definitions based on a bi- or multi-directional understanding of translational research/medicine have been proposed [2-5] and, recently, a strategic outline to successfully implement the goals of this new concept has been outlined in an article by H?rig et al. in Nature Medicine [1].This commentary aims to add a few additional aspects by emphasizing two major factors that strongly influence and, in turn, are influenc
Page 1 /100
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.